Provided by Tiger Trade Technology Pte. Ltd.

Erasca, Inc.

17.63
+0.55003.22%
Post-market: 17.640.0100+0.06%19:48 EDT
Volume:2.45M
Turnover:43.10M
Market Cap:6.17B
PE:-18.16
High:17.84
Open:17.28
Low:17.21
Close:17.08
52wk High:24.28
52wk Low:1.33
Shares:349.76M
Float Shares:291.15M
Volume Ratio:0.97
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9710
EPS(LYR):-0.4393
ROE:-78.25%
ROA:-21.39%
PB:17.04
PE(LYR):-40.14

Loading ...

Verastem Says VS-7375 Trial Data Shows Anti-Tumor Activity in Advanced Solid Tumors

MT Newswires Live
·
Jun 24

Verastem says KRAS G12D inhibitor VS-7375 shows early activity in Phase 1/2 TARGET-D 101 trial across solid tumors

Reuters
·
Jun 24

Erasca, Inc. Faces Federal Securities Lawsuit Over Alleged Misleading Drug Comparisons and Concealed Intellectual Property Risks

TIPRANKS
·
Jun 16

Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Erasca (ERAS) and Incyte (INCY)

TIPRANKS
·
Jun 09

Erasca Shares Rise After BofA Upgrade

MT Newswires Live
·
Jun 05

Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says

MT Newswires Live
·
Jun 04

BofA Securities Upgrades Erasca to Neutral From Underperform, Adjusts Price Target to $16 From $9

MT Newswires Live
·
Jun 04

BeyondSpring names Min Qiu CEO in leadership transition effective July 1, 2026

Reuters
·
Jun 04

Erasca : Bofa Global Research Raises Price Objective to $16.00 From $9.00

THOMSON REUTERS
·
Jun 04

Erasca : Bofa Global Research Raises to Neutral From Underperform Rating

THOMSON REUTERS
·
Jun 04

Erasca Raised to Neutral From Underperform by B of A Securities

Dow Jones
·
Jun 04

Erasca upgraded to Neutral from Underperform at BofA

TIPRANKS
·
Jun 04

Erasca to Present at the Jefferies Global Healthcare Conference

GlobeNewswire
·
May 27

Erasca Merck Pact Puts ERAS 0015 KEYTRUDA Combo In Investor Focus

Simply Wall St.
·
May 21

Movement Alert|Erasca Rises 9.64% in Regular Trading, Trading at $11.3

Market Focus
·
May 21

Erasca releases corporate presentation outlining RAS/MAPK cancer drug pipeline

Reuters
·
May 19

J.P. Morgan Keeps Their Buy Rating on Erasca (ERAS)

TIPRANKS
·
May 14

Erasca Is Maintained at Outperform by Mizuho

Dow Jones
·
May 12

Piper Sandler Remains a Buy on Erasca (ERAS)

TIPRANKS
·
May 12

Analyst Reiterates Buy on ERAS-0015’s Emerging Pan-RAS Potential; $20 Price Target Maintained

TIPRANKS
·
May 12